Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenic response to COVID-19 vaccines in cancer patients on chemotherapy vs non-chemotherapy
TCTR20221001004Completed
- Sponsor
- Chulabhorn Royal Academy
- Start
- Jun 2021
- Countries
- 1
01
Overview
Trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Chulabhorn Royal Academy. Primary endpoint: Immunogenic response to COVID-19 vaccination. Started Jun 2021; status: completed.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20221001004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221001004.